Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Annals of Internal Medicine

Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes

View Full Paper
Ask AI
Bookmark
Share

Authors

UNUlhas M NadgirSASaberi Rana AliJGJagadish Gogate

Discussion

Loading...

Member takes

Overview

Phase 3 trial shows canagliflozin reduced HbA1c in children with type 2 diabetes, suggesting safety similar to adults.

Key Points

  • Canagliflozin significantly lowered HbA1c by 0.76% compared to placebo at week 26.
  • A greater proportion of participants reached HbA1c levels below 6.5% with canagliflozin (36.3%) than with placebo (14.0%).
  • Children and adolescents aged 10 and older were enrolled across 104 sites in 10 countries.
  • The findings highlight a meaningful reduction in HbA1c with canagliflozin, maintaining a safety profile like that observed in adults.

Cite This Study

Nadgir et al. (2025) studied this question.

synapsesocial.com/papers/68c23dc5b210217d6478f6behttps://doi.org/10.7326/annals-24-04017
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes2017 · 7,908 citations